tazobactam has been researched along with spectinomycin in 2 studies
| Studies (tazobactam) | Trials (tazobactam) | Recent Studies (post-2010) (tazobactam) | Studies (spectinomycin) | Trials (spectinomycin) | Recent Studies (post-2010) (spectinomycin) |
|---|---|---|---|---|---|
| 1,327 | 153 | 694 | 1,312 | 87 | 191 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Appelbaum, PC; Jacobs, MR; Spangler, SK | 1 |
2 other study(ies) available for tazobactam and spectinomycin
| Article | Year |
|---|---|
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Drug Combinations; Drug Therapy, Combination; Gram-Negative Anaerobic Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Spectinomycin; Tazobactam; Thienamycins; Virginiamycin | 1993 |